Innoveren Scientific Inc. · OTC:IVRN
Innoveren Scientific — Investor Presentation (December 2023)
20 slides from Innoveren Scientific's investor presentation, Dec 21, 2023
Slide 1: Innoveren Scientific Investor Presentation
Innoveren Scientific Investor Presentation December 2023 OTC: IVRN
Slide 2: Forward Looking Statement
Forward Looking Statement ‘Statements in this release include “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement that is not of historical fact may be deemed “forward-looking”. Words such as “will”, “expect”, “believe”, “project”, “
Slide 3: Introduction
Introduction
Slide 4: Innoveren Scientific At a Glance
Innoveren Scientific At a Glance Innoveren Scientific is a life sciences and biotech incubator focused on advancing new technologies in areas of unmet need across multiple indications with the ultimate goal of improving the lives of patients. Cellular Therapies and Medical Devices to Market Developm
Slide 5: Result Driven Management Team
Result Driven Management Team Michael Yurkowsky—CEO Michael brings more than 30 years of experience in financial services, initially as a broker with several national broker-dealers and as an investment banker. Michael currently serves as the President and Co- Founder of Deverra Therapeutics. Throug
Slide 6: Investment Thesis
Investment Thesis Acquisitive Business Model Constantly evaluating opportunities to enhance the pipeline with potentially life- saving technologies and products. <a . Innovative Products SkinDisc™ and BreatheEasy both have large addressable markets, which will drive future growth as these products m
Slide 7: Product Portfolio
Product Portfolio
Slide 8: SkinDisc™ and BreatheEasy
4 SkinDisc™ Acquired in 2022 From a single application, SkinDisc™ provides an active cellular matrix that maintains complete full wound contact and depth fill during the healing process, resulting in rapid growth of the host tissue. Balanced Portfolio of Short and Long-Term Opportunities BreatheEasy
Slide 9: SkinDisc™
SkinDisc™
Slide 10: SkinDisc™ Overview
SkinDisc™ Overview Overview SkinDisc™ provides an active cellular matrix that maintains complete full wound contact and depth fill during the healing process, resulting in rapid growth of the host tissue. The SkinDisc™ product achieves healing in four to nine weeks, compared to current treatment app
Slide 11: Improving Treatment with SkinDisc™
Improving Treatment with SkinDisc™ SkinDisc™ has the technology and capabilities to revolutionize regenerative wound care by significantly Setting Application Process Application Timing Healing Time reducing time to heal Current Treatment Method Operating room (OR inpatient) and clinic (hospital out
Slide 12: SkinDisc™ Market Opportunity
SkinDisc™ Market Opportunity Of the 500 patients who received SkinDisc™, $2.5 billion’ 85% achieved wound closure within 9 weeks Total market opportunity for Negative Pressure with one application. Wound Therapy (NPWT) units 10% Estimated percent of NPWT cases where SkinDisc™ would be a better treat
Slide 13: Wound Care Market
Wound Care Market Wound Care involves every stage of wound management, such as diagnosing the wound type factors that affect wound healing, and proper treatments. Wound Care Market Trajectory’ ss $30 6.3% 325 szo $18.5 st su 3 so 202 2023 2024 ©2025 2026-2027 «2028 «2029-2030 cAGR $30.0 Billions ($}
Slide 14: BreatheEasy
BreatheEasy
Slide 15: BreatheEasy Overview
BreatheEasy Overview Overview BreatheEasy is a 510(k) de novo pathway medical device that is an autologous IV infusion for patients struggling with Chronic Obstructive Pulmonary Disease {COPD}, as well as other closely related diseases such as chronic bronchitis and emphysema. BreatheEasy Technology
Slide 16: BreatheEasy Market Opportunity
BreatheEasy Market Opportunity COPD refers to a group of diseases that cause airflow blockage and breathing-related problems. It is currently the fourth leading cause of death for Americans?. The COPD Treatment Market Trajectory” 4.6% cAGR $305 $25 s20 5296 sas sto $5 $0 2022 2023 2024 2025 2026 202
Slide 17: Research & Development
Research & Development
Slide 18: Product Pipeline
Product Pipeline Innoveren Scientific has a balanced product pipeline of both short- and long-term opportunities, which position the Company to not only achieve operational success but also maximize its return on investment. Current Product SkinDisc™ Lite Clinical Wound Healing SkinDisc™ Limb Salvag
Slide 19: Areas of Interest
Areas of Interest Outside of the Company’s current pipeline, Innoveren Scientific has interest in expanding its portfolio with additional next-generation cellular therapies and medical devices that will improve the lives of patients around the world with life-threatening diseases and chronic health
Slide 20: Contact Us
Contact Us IVRN@alpha-ir.com
Innoveren Scientific — Investor Presentation (December 2023) on 6ix